Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $985 | 6-8 weeks | |
50 mg | $1,280 | 6-8 weeks | |
100 mg | $1,940 | 6-8 weeks |
Description | CMC2.24 (TRB-N0224) is an orally active tricarbonylmethane agent that demonstrates effectiveness in inhibiting Ras activation and the downstream effector ERK1/2 pathway, thus effectively combating pancreatic tumor formation in mice. Additionally, CMC2.24 exerts potent inhibitory effects on zinc-dependent MMPs, with IC50s ranging from 2.0-69 μM. Furthermore, CMC2.24 aids in alleviating the progression of osteoarthritis by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis through the NF-κB/HIF-2α axis[1][2][3]. |
Targets&IC50 | MMP13:2.7 μM (IC50), MMP12:2 μM (IC50), MMP9:8 μM (IC50), MMP8:4.5 μM (IC50), MMP2:4.8 μM (IC50), MMP1:69.8 μM (IC50), MMP14:15.3 μM (IC50), MMP7:5 μM (IC50), MMP3:2.9 μM (IC50) |
In vitro | CMC2.24 (0-60 μM; 24 hours) inhibits pancreatic cancer growth in vitro by reducing STAT3Ser727 phosphorylation levels, inducing mitochondrial reactive oxygen species, and promoting intrinsic apoptosis and mitochondrial cell death in pancreatic cancer cells[1]. |
In vivo | CMC2.24 (50 mg/kg; p.o.; five times per week for 17 days) inhibits pancreatic cancer xenograft growth and human PC through a potent cytokinetic effect, and disrupts the ERK signaling pathway in PC cells and xenografts[1]. |
Molecular Weight | 427.45 |
Formula | C26H21NO5 |
Cas No. | 1255639-43-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: < 1 mg/mL (insoluble or slightly soluble) |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.